Pentwater Capital Management’s Adicet Bio ACET Stock Holding History

Pentwater Capital Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-232	Closed	-$177K	–	182
2019 Q1	$177K	Buy	+232	New	+$211K	﹤0.01%	135

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pentwater Capital Management's ACET Position: Q2 2019 in Review

Pentwater Capital Management sold out of Adicet Bio (ACET) in Q2 2019, closing a stake of 232 shares — an estimated $177K sold.

Pentwater Capital Management first reported a position in ACET in Q1 2019 and held it in 1 quarter. The position peaked at $177K in Q1 2019. 48 funds tracked by Wall St. Rank hold ACET as of Q2 2019.

Pentwater Capital Management reported no remaining Adicet Bio position as of Q2 2019 after selling out during the quarter.
Pentwater Capital Management sold 232 Adicet Bio shares in Q2 2019, an estimated $177K.
Pentwater Capital Management first reported a position in Adicet Bio in Q1 2019 and held it in 1 quarter.
Pentwater Capital Management's Adicet Bio position peaked at $177K in Q1 2019.
48 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2019.

Based on Pentwater Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.